Interferon alpha inhibits hepatocellular carcinoma growth through inducing apoptosis and interfering with adhesion of tumor endothelial cells

Cancer Letters

Volumn 290, Issue 2, 2010, Pages 204-210

  Zhang, Ti ^a   Sun, Hui Chuan ^b   Zhou, Hong Yuan ^a   Luo, Jing Tao ^a   Zhang, Bai Lin ^a   Wang, Peng ^a   Wang, Lu ^b   Qin, Lun Xiu ^b   Ren, Ning ^b   Ye, Sheng Long ^b   Li, Qiang ^a   Tang, Zhao You ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Angiogenesis; Hepatocellular carcinoma; Interferon alpha; Tumor endothelium

Indexed keywords

ALPHA INTERFERON; ALPHA SMOOTH MUSCLE ACTIN; CD31 ANTIGEN; LOW DENSITY LIPOPROTEIN; VASCULAR ENDOTHELIAL CADHERIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL ADHESION; CELL CONTACT; CONTROLLED STUDY; DNA MICROARRAY; DRUG MECHANISM; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NICK END LABELING; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL ADHESION; CELL LINE, TUMOR; ENDOTHELIAL CELLS; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; INTERFERON-ALPHA; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 77649182103     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.09.009     Document Type: Article

References (32)

1. Llovet J.M., Burroughs A., and Bruix J. Hepatocellular carcinoma. Lancet 362 (2003) 1907-1917
2. Poon R.T., Lau C., Pang R., Ng K.K., Yuen J., and Fan S.T. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann. Surg. Oncol. 14 (2007) 1835-1845
3. Wang L., Tang Z.Y., Qin L.X., Wu X.F., Sun H.C., Xue Q., and Ye S.L. High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatology 32 (2000) 43-48
4. Wang L., Wu W.Z., Sun H.C., Wu X.F., Qin L.X., Liu Y.K., Liu K.D., and Tang Z.Y. Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J. Gastrointest. Surg. 7 (2003) 587-594
5. Wu W.Z., Sun H.C., Gao Y.Q., Li Y., Wang L., Zhou K., Liu K.D., Iliakis G., and Tang Z.Y. Reduction in p48-ISGFgamma levels confers resistance to interferon-alpha2a in MHCC97 cells. Oncology 67 (2004) 428-440
6. Wu W.Z., Sun H.C., Shen Y.F., Chen J., Wang L., Tang Z.Y., Iliakis G., and Liu K.D. Interferon alpha 2a downregulates VEGF expression through PI3 kinase and MAP kinase signaling pathways. J. Cancer Res. Clin. Oncol. 131 (2005) 169-178
7. Lin S.M., Lin C.J., Hsu C.W., Tai D.I., Sheen I.S., Lin D.Y., and Liaw Y.F. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 100 (2004) 376-382
8. Sun H.C., Tang Z.Y., Wang L., Qin L.X., Ma Z.C., Ye Q.H., Zhang B.H., Qian Y.B., Wu Z.Q., Fan J., Zhou X.D., Zhou J., Qiu S.J., and Shen Y.F. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J. Cancer Res. Clin. Oncol. 132 (2006) 458-465
9. Lo C.M., Liu C.L., Chan S.C., Lam C.M., Poon R.T., Ng I.O., Fan S.T., and Wong J. A randomized, Controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann. Surg. 245 (2007) 831-842
10. Bergers G., and Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3 (2003) 401-410
11. Cleaver O., and Melton D.A. Endothelial signaling during development. Nat. Med. 9 (2003) 661-668
12. Zhang T., Sun H.C., Xu Y., Zhang K.Z., Wang L., Qin L.X., Wu W.Z., Liu Y.K., Ye S.L., and Tang Z.Y. Overexpression of platelet-derived growth factor receptor alpha in endothelial cells of hepatocellular carcinoma associated with high metastatic potential. Clin. Cancer Res. 11 (2005) 8557-8563
13. Sun F.X., Tang Z.Y., Lui K.D., Ye S.L., Xue Q., Gao D.M., and Ma Z.C. Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues. Int. J. Cancer 66 (1996) 239-243
14. Tian J., Tang Z.Y., Ye S.L., Liu Y.K., Lin Z.Y., Chen J., and Xue Q. New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expressions of the factors associated with metastasis. Brit. J. Cancer 81 (1999) 814-821
15. Li Y., Tang Z.Y., Ye S.L., Liu Y.K., Chen J., Xue Q., Gao D.M., and Bao W.H. Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J. Gastroenterol. 7 (2001) 630-636
16. Deregibus M.C., Cantaluppi V., Doublier S., Brizzi M.F., Deambrosis I., Albini A., and Camussi G. HIV-1-Tat protein activates phosphatidylinositol 3-kinase/ AKT-dependent survival pathways in Kaposi's sarcoma cells. J. Biol. Chem. 277 (2002) 25195-25202
17. Uehara H., Kim S.J., Karashima T., Shepherd D.L., Fan D., Tsan R., Killion J.J., Logothetis C., Mathew P., and Fidler I.J. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J. Natl. Cancer Inst. 95 (2003) 458-470
18. Kim S.J., Uehara H., Yazici S., Langley R.R., He J., Tsan R., Fan D., Killion J.J., and Fidler I.J. Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice. Cancer Res. 64 (2004) 4201-4208
19. Contag C.H., and Bachmann M.H. Molecular medicine: the writing is on the vessel wall. Nature 429 (2004) 618-619
20. Langley R.R., Fan D., Tsan R.Z., Rebhun R., He J., Kim S.J., and Fidler I.J. Activation of the platelet-derived growth factor-receptor enhances survival of murine bone endothelial cells. Cancer Res. 64 (2004) 3727-3730
21. Yokoi K., Sasaki T., Bucana C.D., Fan D., Baker C.H., Kitadai Y., Kuwai T., Abbruzzese J.L., and Fidler I.J. Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. Cancer Res. 65 (2005) 10371-10380
22. Kaiser W.J., Kaufman J.L., and Offermann M.K. IFN-alpha sensitizes human umbilical vein endothelial cells to apoptosis induced by double-stranded RNA. J. Immunol. 172 (2004) 1699-1710
23. Solorzano C.C., Hwang R., Baker C.H., Bucana C.D., Pisters P.W., Evans D.B., Killion J.J., and Fidler I.J. Administration of optimal biological dose and schedule of interferon alpha combined with gemcitabine induces apoptosis in tumor-associated endothelial cells and reduces growth of human pancreatic carcinoma implanted orthotopically in nude mice. Clin. Cancer Res. 9 (2003) 1858-1867
24. Saunders W.B., Bohnsack B.L., Faske J.B., Anthis N.J., Bayless K.J., Hirschi K.K., and Davis G.E. Coregulation of vascular tube stabilization by endothelial cell TIMP-2 and pericyte TIMP-3. J. Cell Biol. 175 (2006) 179-191
25. Jain R.K. Molecular regulation of vessel maturation. Nat. Med. 9 (2003) 685-693
26. Gorog P., and Pearson J.D. Surface determinants of low density lipoprotein uptake by endothelial cells. Atherosclerosis 53 (1984) 21-29
27. Smalley D.M., Lin J.H., Curtis M.L., Kobari Y., Stemerman M.B., and Pritchard Jr. K.A. Native LDL increases endothelial cell adhesiveness by inducing intercellular adhesion molecule-1. Arterioscler. Thromb. Vasc. Biol. 16 (1996) 585-590
28. May C., Doody J.F., Abdullah R., Balderes P., Xu X., Chen C.P., Zhu Z., Shapiro L., Kussie P., Hicklin D.J., Liao F., and Bohlen P. Identification of a transiently exposed VE-cadherin epitope that allows for specific targeting of an antibody to the tumor neovasculature. Blood 105 (2005) 4337-4344
29. Navarro P., Ruco L., and Dejana E. Differential localization of VE- and N-cadherins in human endothelial cells: VE-cadherin competes with N-cadherin for junctional localization. J. Cell Biol. 140 (1998) 1475-1484
30. Menon C., Ghartey A., Canter R., Feldman M., and Fraker D.L. Tumor necrosis factor-alpha damages tumor blood vessel integrity by targeting VE-cadherin. Ann. Surg. 244 (2006) 781-791
31. Gavard J., and Gutkind J.S. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat. Cell Biol. 8 (2006) 1223-1234
32. Kouklis P., Konstantoulaki M., and Malik A.B. VE-cadherin-induced Cdc42 signaling regulates formation of membrane protrusions in endothelial cells. J. Biol. Chem. 278 (2003) 16230-16236